MDGL

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc. (MDGL) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.8) B (3.3) A- (4.0) C (2.4) C+ (2.6) B- (3.0)
2026-11-06 C+ (2.7) A- (3.9) A- (4.0) C+ (2.5) C+ (2.7) B (3.2)
2026-10-30 C+ (2.6) A- (4.1) A- (4.0) C+ (2.8) A+ (5.0) B+ (3.7)
2026-10-23 C+ (2.6) A- (4.1) A- (4.0) C (2.5) A+ (5.0) B+ (3.6)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe